Managers / Q3 2022
Consonance Capital Management LP
CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062
Summary
Consonance Capital Management LP reported $7M in U.S.-listed holdings across 2 positions for Q3 2022.
The portfolio is heavily concentrated: SRZNW alone accounts for 100.0% of reported value.
Compared with Q2 2022, the fund opened 0 new positions and exited 5.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 97.0% · $7M
- Equity WRT · 3.0% · $215,000
Quarter-over-Quarter Changes full breakdown →
vs Q2 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SLNSILENCE THERAPEUTICS PLC | SOLD OUT | −634.3K | 0 | −$8M | $0 |
| CMPXCOMPASS THERAPEUTICS INC | SOLD OUT | −1.60M | 0 | −$4M | $0 |
| UTHRUNITED THERAPEUTICS CORP DEL | SOLD OUT | −3.0K | 0 | −$706,000 | $0 |
| GMEDGLOBUS MED INC | SOLD OUT | −5.4K | 0 | −$303,000 | $0 |
| TNDMTANDEM DIABETES CARE INC | SOLD OUT | −4.3K | 0 | −$254,000 | $0 |
| SURROZEN INC | HELD | +0 | 3.50M | −$3M | $7M |
| SRZNWSURROZEN INC | HELD | +0 | 1.17M | −$8,000 | $215,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | SRZNWSURROZEN INC | COM · *W EXP 08/01/203 | 100.00% | $7M | 4.66M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2022 | $7M | 2 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $24M | 7 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $59M | 8 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $153M | 15 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $183M | 17 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $831M | 32 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $938M | 35 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.1B | 38 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $821M | 27 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $1.7B | 32 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $1.3B | 31 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $1.6B | 35 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $1.0B | 30 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $1.4B | 30 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $1.6B | 26 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.